Antistolling na myocardinfarct: uit te meten?

Slides (presentatie) - 3 mrt. 2011

Dia 2

Mortality in hospital and at 6 months in low, intermediate and high risk categories in registry populations according to the GRACE Risk score

Question: Strategy ?

Relative risk of all cause of mortality

Management Strategy

Time to catheterization (hrs)

Dia 8

A.S.A.P < 24 h vs delayed > 36h - ACS met 2/3 > 60 y, pos marker (76%), ischemic ECG (80%) and revasc possible

No early hazard!

GRACE > 141 14% 21% p=0.009 Major bleeds 3.1 3.5% p=0.53

Early (≤24 h, median=14h) or delayed intervention ( ≥36 h, median=50h) N=3000

Early (≤24 h, median=14h) or delayed intervention ( ≥36 h, median=50h)

Why not immediately “STEMI-like”?

ABOARD study design

Index ACS event

In-hospital medications

Time to catheterization (hrs)

Primary EP (peak of troponin I)

Composite Ischemic Endpoints at 1 month

Safety outcomes at 1 month

Hospital stay

Summary: TIMACS and ABOARD

Question: Strategy ?

Q: GPIIbIIIa inhibitors ? When ?

GPIIbIIIa Inhibitors

Efficacity GPIIBIIIA in NSTE ACS only if PCI !!!


If GPIIbIIIa: - Upstream for all high risk NSTE ACS ? - or selectively downstream if PCI ?


Delayed Provisional GPIIbIIIa: Same Ischemic benefit Lower bleeding risk

30-day Death or MI Prespecified Subgroups

Summary for GPIIbIIIa

Q: GPIIbIIIa inhibitors ? When ?

Q: Antiplatelet Therapy: P2Y12 inhibitors in CCU ?

Alternatives Molecules

Montalescot et al. JACC 2006

Q: Antiplatelet Therapy: P2Y12 inhibitors in CCU ?

Antiplatelet Drugs

Study Design, Flow and Compliance

Clopidogrel: Double vs Standard Dose Primary Outcome and Components

Clopidogrel: Double vs Standard Dose Primary Outcome: PCI Patients

Clopidogrel Double vs Standard Dose Bleeding PCI Population at 30 days

Conclusions Clopidogrel Dose Comparison


Primary Endpoint: CV Death,MI,Stroke

Balance of Efficacy and Safety


Diabetic Subgroup

Ischemic Risk

BLEEDING RISK: subgroups

Tailored for Bleeding Risk ?

P2Y12 inhibitors for PCI/ACS in 2011

Q: Antiplatelet Therapy: P2Y12 inhibitors in CCU ?

Platelet Function Tests

Composite of death, non-fatal myocardial infarction, definite stent thrombosis and stroke POPular study JAMA 2010

Cut-Off values Based on Clinical Endpoints in Prospective Studies

Risk for recurrent events concentrated in patients with highest on-treatment reactivity

POPular Risc Score

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATO trial

Ticagrelor (AZD 6140): an oral reversible P2Y12 antagonist

PLATO study design

K-M estimate of time to first primary efficacy event (composite of CV death, MI or stroke)

Time to major bleeding – primary safety event

Non-CABG and CABG-related major bleeding

Safety = TIMI Major Non-CABG Bleeds (12-15 months)



Platelet Aggregation at 4 hours


Safety = TIMI Major Non-CABG Bleeds (12-15 months)

Tailor-made medicine?

Marked interindividual response to antiplatelet drugs

Residual or On-Treatment Platelet Reactivity

Do Platelet Function Assays Predict Clinical Outcomes in clopidogrel pretreated patients undergoing elective PCI The POPular-study. JAMA 2010;303:754-62

Tests more physiological shear-dependent

POPular Risk Score

Rate of CABG patients and TIMI Major Bleeds

Summmary: P2Y12 inhibition for tomorrow

Compliance and ST

With more potent P2Y12 inhibitors: How to reduce Bleeding Risk in ACS ?

Low Dose of Aspirin

ASA Dose Comparison Primary Outcome and Bleeding

Use of PPI

Radial Access




Similar for DES

MACC with BMS and non-cardiac surgery N=899

Bleeds with DES and Non-cardiac Surgery


Summary for ACS: 2011

Discharge therapy

Tailored Therapy PCI in ACS ?

Discontinue antithrombotica

Deze inhoud is bedoeld voor medische professionals. Om dit te bekijken is registratie noodzakelijk. Registreer gratis voor onbeperkte toegang tot ons educatief materiaal.

Deel deze pagina met collega's en vrienden: